Generic Rhopressa Availability

Last updated on Apr 10, 2025.

Rhopressa is a brand name of netarsudil ophthalmic, approved by the FDA in the following formulation(s):

RHOPRESSA (netarsudil mesylate - solution/drops;ophthalmic)

Manufacturer: ALCON LABS INC
Approval date: December 18, 2017
Strength(s): EQ 0.02% BASE ^[RLD]

Is there a generic version of Rhopressa available?

No. There is currently no therapeutically equivalent version of Rhopressa available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Rhopressa. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

Related patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

Dual mechanism inhibitors for the treatment of disease
Patent 10,174,017
Issued: January 8, 2019
Inventor(s): deLong Mitchell A. & Sturdivant Jill M. & Royalty Susan M.
Assignee(s): Aerie Pharmaceuticals, Inc.
Provided are compounds that are inhibitors of both rho kinase and of a monoamine transporter (MAT) act to improve the disease state or condition. Further provided are compositions comprising the compounds. Further provided are methods for treating diseases or conditions, the methods comprising administering compounds according to the invention. One such disease may be glaucoma for which, among other beneficial effects, a marked reduction in intraocular pressure (IOP) may be achieved.
Patent expiration dates:
- January 27, 2030
  ✓
  Patent use: REDUCTION OF ELEVATED INTRAOCULAR PRESSURE
  ✓
  Drug substance
  ✓
  Drug product
Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
Patent 10,532,993
Issued: January 14, 2020
Inventor(s): deLong Mitchell A. & Sturdivant Jill Marie & Royalty Susan M.
Assignee(s): Aerie Pharmaceuticals, Inc.
Disclosed are beta and gamma-amino isoquinoline amide compounds and substituted benzamide compounds. In particular, the invention provides compounds that affect the function of kinases in a cell and that are useful as therapeutic agents or with therapeutic agents. The compounds of the invention are useful in the treatment of a variety of diseases and conditions including eye diseases such as glaucoma, cardiovascular diseases, and diseases characterized by abnormal growth, such as cancers. The invention further provides compositions containing the beta or gamma-amino isoquinoline amide compounds or substituted benzamide compounds.
Patent expiration dates:
- July 11, 2026
  ✓
  Patent use: REDUCTION OF ELEVATED INTRAOCULAR PRESSURE
Combination therapy
Patent 10,588,901
Issued: March 17, 2020
Inventor(s): Kopczynski Casey & Lin Cheng-Wen & Sturdivant Jill Marie & deLong Mitchell A.
Assignee(s): Aerie Pharmaceuticals, Inc.
Described herein are compounds and compositions for treating glaucoma and/or reducing intraocular pressure. Compositions may comprise an isoquinoline compound and a prostaglandin or a prostaglandin analog. Compounds described herein include those in which an isoquinoline compound is covalently linked to a prostaglandin or a prostaglandin analog, and those in which an isoquinoline compound and a prostaglandin free acid together form a salt.
Patent expiration dates:
- March 14, 2034
  ✓
  Patent use: REDUCTION OF ELEVATED INTRAOCULAR PRESSURE
  ✓
  Drug substance
  ✓
  Drug product
Dual mechanism inhibitors for the treatment of disease
Patent 10,654,844
Issued: May 19, 2020
Inventor(s): deLong Mitchell A. & Sturdivant Jill Marie & Royalty Susan M.
Assignee(s): Aerie Pharmaceuticals, Inc.
Provided are compounds that are inhibitors of both rho kinase and of a monoamine transporter (MAT) act to improve the disease state or condition. Further provided are compositions comprising the compounds. Further provided are methods for treating diseases or conditions, the methods comprising administering compounds according to the invention. One such disease may be glaucoma for which, among other beneficial effects, a marked reduction in intraocular pressure (IOP) may be achieved.
Patent expiration dates:
- January 27, 2030
  ✓
  Patent use: REDUCTION OF ELEVATED INTRAOCULAR PRESSURE
  ✓
  Drug substance
  ✓
  Drug product
Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
Patent 10,882,840
Issued: January 5, 2021
Inventor(s): deLong Mitchell A. & Sturdivant Jill Marie & Royalty Susan M.
Assignee(s): Aerie Pharmaceuticals, Inc.
Disclosed are beta and gamma-amino isoquinoline amide compounds and substituted benzamide compounds. In particular, the invention provides compounds that affect the function of kinases in a cell and that are useful as therapeutic agents or with therapeutic agents. The compounds of the invention are useful in the treatment of a variety of diseases and conditions including eye diseases such as glaucoma, cardiovascular diseases, and diseases characterized by abnormal growth, such as cancers. The invention further provides compositions containing the beta or gamma-amino isoquinoline amide compounds or substituted benzamide compounds.
Patent expiration dates:
- July 11, 2026
  ✓
  Patent use: REDUCTION OF ELEVATED INTRAOCULAR PRESSURE
Combination therapy
Patent 11,020,385
Issued: June 1, 2021
Inventor(s): Kopczynski Casey & Lin Cheng-Wen & Sturdivant Jill Marie & deLong Mitchell A.
Assignee(s): Aerie Pharmaceuticals, Inc.
Described herein are compounds and compositions for treating glaucoma and/or reducing intraocular pressure. Compositions may comprise an isoquinoline compound and a prostaglandin or a prostaglandin analog. Compounds described herein include those in which an isoquinoline compound is covalently linked to a prostaglandin or a prostaglandin analog, and those in which an isoquinoline compound and a prostaglandin free acid together form a salt.
Patent expiration dates:
- March 14, 2034
  ✓
  Patent use: REDUCTION OF ELEVATED INTRAOCULAR PRESSURE
Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
Patent 11,021,456
Issued: June 1, 2021
Inventor(s): deLong Mitchell A. & Sturdivant Jill Marie & Royalty Susan M.
Assignee(s): Aerie Pharmaceuticals, Inc.
Disclosed are beta and gamma-amino isoquinoline amide compounds and substituted benzamide compounds. In particular, the invention provides compounds that affect the function of kinases in a cell and that are useful as therapeutic agents or with therapeutic agents. The compounds of the invention are useful in the treatment of a variety of diseases and conditions including eye diseases such as glaucoma, cardiovascular diseases, and diseases characterized by abnormal growth, such as cancers. The invention further provides compositions containing the beta or gamma-amino isoquinoline amide compounds or substituted benzamide compounds.
Patent expiration dates:
- July 11, 2026
  ✓
  Patent use: REDUCTION OF ELEVATED INTRAOCULAR PRESSURE
Dual mechanism inhibitors for the treatment of disease
Patent 11,028,081
Issued: June 8, 2021
Inventor(s): deLong Mitchell A. & Sturdivant Jill Marie & Royalty Susan M.
Assignee(s): Aerie Pharmaceuticals, Inc.
Provided are compounds that are inhibitors of both rho kinase and of a monoamine transporter (MAT) act to improve the disease state or condition. Further provided are compositions comprising the compounds. Further provided are methods for treating diseases or conditions, the methods comprising administering compounds according to the invention. One such disease may be glaucoma for which, among other beneficial effects, a marked reduction in intraocular pressure (IOP) may be achieved.
Patent expiration dates:
- January 27, 2030
  ✓
  Patent use: REDUCTION OF ELEVATED INTRAOCULAR PRESSURE
Compositions for treating glaucoma or reducing intraocular pressure
Patent 11,185,538
Issued: November 30, 2021
Inventor(s): Kopczynski Casey & Lin Cheng-Wen & Sturdivant Jill Marie & deLong Mitchell A.
Assignee(s): Aerie Pharmaceuticals, Inc.
Described herein are compounds and compositions for treating glaucoma and/or reducing intraocular pressure. Compositions may comprise an isoquinoline compound and a prostaglandin or a prostaglandin analog. Compounds described herein include those in which an isoquinoline compound is covalently linked to a prostaglandin or a prostaglandin analog, and those in which an isoquinoline compound and a prostaglandin free acid together form a salt.
Patent expiration dates:
- March 14, 2034
  ✓
  Drug product
Dual mechanism inhibitors for the treatment of disease
Patent 11,618,748
Issued: April 4, 2023
Inventor(s): deLong; Mitchell A. et al.
Assignee(s): Aerie Pharmaceuticals, Inc. (Bedminster, NJ)
Provided are compounds that are inhibitors of both rho kinase and of a monoamine transporter (MAT) act to improve the disease state or condition. Further provided are compositions comprising the compounds. Further provided are methods for treating diseases or conditions, the methods comprising administering compounds according to the invention. One such disease may be glaucoma for which, among other beneficial effects, a marked reduction in intraocular pressure (IOP) may be achieved.
Patent expiration dates:
- January 27, 2030
  ✓
  Patent use: REDUCTION OF ELEVATED INTRAOCULAR PRESSURE
Dual mechanism inhibitors for the treatment of disease
Patent 8,394,826
Issued: March 12, 2013
Inventor(s): deLong Mitchell A. & Sturdivant Jill Marie & Royalty Susan M.
Assignee(s): Aerie Pharmaceuticals, Inc.
Provided are compounds that are inhibitors of both rho kinase and of a monoamine transporter (MAT) act to improve the disease state or condition. Further provided are compositions comprising the compounds. Further provided are methods for treating diseases or conditions, the methods comprising administering compounds according to the invention. One such disease may be glaucoma for which, among other beneficial effects, a marked reduction in intraocular pressure (IOP) may be achieved.
Patent expiration dates:
- November 10, 2030
  ✓
  Patent use: REDUCTION OF ELEVATED INTRAOCULAR PRESSURE
  ✓
  Drug substance
  ✓
  Drug product
Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
Patent 8,450,344
Issued: May 28, 2013
Inventor(s): deLong Mitchell A. & Sturdivant Jill Marie & Royalty Susan M.
Assignee(s): Aerie Pharmaceuticals, Inc.
Disclosed are beta and gamma-amino isoquinoline amide compounds and substituted benzamide compounds. In particular, the invention provides compounds that affect the function of kinases in a cell and that are useful as therapeutic agents or with therapeutic agents. The compounds of the invention are useful in the treatment of a variety of diseases and conditions including eye diseases such as glaucoma, cardiovascular diseases, and diseases characterized by abnormal growth, such as cancers. The invention further provides compositions containing the beta or gamma-amino isoquinoline amide compounds or substituted benzamide compounds.
Patent expiration dates:
- July 11, 2026
  ✓
  Patent use: REDUCTION OF ELEVATED INTRAOCULAR PRESSURE
  ✓
  Drug substance
  ✓
  Drug product
Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
Patent 9,096,569
Issued: August 4, 2015
Inventor(s): deLong Mitchell A. & Sturdivant Jill Marie & Royalty Susan M.
Assignee(s): Aerie Pharmaceuticals, Inc.
Disclosed are beta and gamma-amino isoquinoline amide compounds and substituted benzamide compounds. In particular, the invention provides compounds that affect the function of kinases in a cell and that are useful as therapeutic agents or with therapeutic agents. The compounds of the invention are useful in the treatment of a variety of diseases and conditions including eye diseases such as glaucoma, cardiovascular diseases, and diseases characterized by abnormal growth, such as cancers. The invention further provides compositions containing the beta or gamma-amino isoquinoline amide compounds or substituted benzamide compounds.
Patent expiration dates:
- July 11, 2026
  ✓
  Patent use: REDUCTION OF ELEVATED INTRAOCULAR PRESSURE
  ✓
  Drug substance
  ✓
  Drug product
Combination therapy
Patent 9,415,043
Issued: August 16, 2016
Inventor(s): Kopczynski Casey & Lin Cheng-Wen & Sturdivant Jill Marie & deLong Mitchell A.
Assignee(s): Aerie Pharmaceuticals, Inc.
Described herein are compounds and compositions for treating glaucoma and/or reducing intraocular pressure. Compositions may comprise an isoquinoline compound and a prostaglandin or a prostaglandin analog. Compounds described herein include those in which an isoquinoline compound is covalently linked to a prostaglandin or a prostaglandin analog, and those in which an isoquinoline compound and a prostaglandin free acid together form a salt.
Patent expiration dates:
- March 14, 2034
  ✓
  Drug substance
Combination therapy
Patent 9,931,336
Issued: April 3, 2018
Inventor(s): Kopczynski Casey & Lin Cheng-Wen & Sturdivant Jill Marie & deLong Mitchell A.
Assignee(s): Aerie Pharmaceuticals, Inc.
Described herein are compounds and compositions for treating glaucoma and/or reducing intraocular pressure. Compositions may comprise an isoquinoline compound and a prostaglandin or a prostaglandin analog. Compounds described herein include those in which an isoquinoline compound is covalently linked to a prostaglandin or a prostaglandin analog, and those in which an isoquinoline compound and a prostaglandin free acid together form a salt.
Patent expiration dates:
- March 14, 2034
  ✓
  Patent use: REDUCTION OF ELEVATED INTRAOCULAR PRESSURE
  ✓
  Drug substance
  ✓
  Drug product

More about Rhopressa (netarsudil ophthalmic)

Patient resources

Professional resources

Related treatment guides

Glossary

Term	Definition
Drug Patent	A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug Exclusivity	Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLD	A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer

Drug Status

Availability Prescription only Rx

Pregnancy & Lactation Risk data available

CSA Schedule* Not a controlled drug N/A

Approval History Drug history at FDA

User Reviews & Ratings

3.9 / 10

36 Reviews